IgG index and not serum 25-hydroxyvitamin D is associated with age at onset of multiple sclerosis.

Pernilla Stridh^{1,2}, Ingrid Kockum^{1,2*}, Jesse Huang^{1,2*}

1. Center of Molecular Medicine, Karolinska University Hospital, Solna, Sweden.

2. Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden.

* Equal contribution

Running Title

Vitamin D and age at onset in MS.

Keywords

Multiple sclerosis, age at onset, vitamin D, 25(OH)D, IgG index

Correspondence

Jesse Huang

jesse.huang@ki.se

Centrum for Molecular Medicine, L8:05

SE-171 76 Stockholm, Sweden

Abstract

Background

Vitamin D deficiency is associated with an increased risk of multiple sclerosis (MS). However, its effect on the age of disease onset remains unclear. This study examines the relationship between serum 25 hydroxyvitamin D (25(OH)D) levels and age of first symptom onset among recently diagnosed MS patients.

Method

Serum 25(OH)D was measured from forty MS patients sampled near disease onset. After correcting seasonal variability, a multivariable linear regression was used to examine associations to age at onset.

Results

Serum 25(OH)D was not correlated with age at onset ($P > 0.5$). However, CSF IgG index was lower among patients with later disease onset ($\beta = -5.35$, $P = 0.028$). Furthermore, we observed bias resulting from non-random distribution of sampling by season, which after correcting indicates a higher 25(OH)D level among patients sampled at relapse compared to remission, instead of lower as previously reported.

Conclusion

In summary, serum 25(OH)D was not associated with the age at onset.

Abbreviations

25(OH)D - 25-hydroxyvitamin D₃

CSF - cerebrospinal fluid

EDSS - expanded disability status scale

MS - multiple sclerosis

OCB - oligoclonal band

PPMS - primary progressive multiple sclerosis

RRMS - relapsing-remitting multiple sclerosis

UV - ultraviolet

Introduction

Vitamin D is essential for proper immune regulation, and long-term deficiencies commonly due to inadequate sun exposure and dietary supplementation have been associated with increased autoimmunity [1]. Low sun exposure has also been associated with an increased risk of multiple sclerosis (MS) [2,3], a chronic neuroinflammatory disease of the central nervous system. Geographic gradients in MS prevalence, corresponding with latitude and ultraviolet radiation (UVR) levels, has been consistently reported in previous studies [4-6]. Emphasis on early childhood exposures indicates vitamin D is likely involved in the early stages of disease development [3,7]; however, its direct influence on the age at onset or the incidence of pediatric-onset disease remains unclear [3,8,9]. This study investigates the association between vitamin D and age at first symptom onset among recently diagnosed MS patients while also examining effects from seasonal variability using data from Soilu-Hänninen et al. [10].

Material and Methods

The study cohort and all sampling and analysis protocols have been previously described [10]. In summary, forty MS patients were enrolled from two Finnish neurology clinics between 2000 and 2003, with serum sampled at or near disease onset. Serum 25 hydroxyvitamin D (25(OH)D, nmol/L), a stable precursor commonly used to assess overall vitamin D deficiency, was determined using a commercial I25 radioimmunoassay. Cerebrospinal fluid (CSF) was sampled to determine the CSF IgG index and the presence of oligoclonal bands (OCB). Summary statistics of the study cohort are provided in Table 1.

Serum 25(OH)D levels naturally oscillate due to seasonal variation in sun/UV-B exposure, an important source for vitamin D production in addition to diet and supplementation. Levels tend to peak in the summer and drop in the winter. As previously detailed [7], 25(OH)D levels were adjusted for seasonal variability using a periodic regression model of $\sin(2\pi x/12) + \cos(2\pi x/12)$, with “x” defined by the month of sampling. Residuals were then added to the mean determined by the model to calculate the season-adjusted 25(OH)D level.

Associations were analyzed using either a Student t-test or a multivariable linear regression model adjusting for sex, age at sampling, and other relevant disease characteristics. The expanded disability status scale (EDSS), assessed at the time of sampling, was dichotomized by ≥ 2 , corresponding to at least minimal disability in one functional system. All statistical analyses were performed using R v.4.0.3 (Vienna, Austria).

Results

Figure 1 shows the periodic seasonal variability in serum 25(OH)D levels, with the highest levels observed in the summer and lowest in late winter.

There is a higher proportion of MS patients sampled during relapse between March and May. The risk of sampling a patient undergoing relapse within the period as determined by Fischer’s exact test is OR=6.132 (95% confidence interval=0.63-312, P=0.10). Furthermore, this period corresponds with a naturally lower serum 25(OH)D, which explains the previous observation of lower serum 25(OH)D levels among those sampled during relapse compared to remission ($\beta=-13.9$, SE=6.0, P=0.026) [10]. Following correction of seasonal variation (**Figure 1**, right panel),

serum 25(OH)D levels among MS patients sampled at relapse were higher than at remission ($\beta=12.0$, $SE=5.3$, $P=0.029$).

A similar effect was observed when comparing 25(OH)D levels by sex. There was a higher proportion of females between June and August ($P=0.03$) and a moderately higher proportion of males in the winter between December and March ($P=0.059$). This also results in a switch in effect (uncorrected: $\beta=19.3$, $SE=7.1$, $P=0.01$), with females having lower 25(OH)D than males (corrected: $\beta=-13.0$, $SE=6.8$, $P=0.06$).

Serum 25(OH)D concentration at sampling was not associated with age at onset ($P>0.5$), even after correcting for sex and other disease characteristics (**Table 2**). Similarly, Pearson and Spearman correlation coefficients were only $\rho=0.02$ and $\rho=0.08$, respectively. However, CSF IgG index was negatively correlated with age at onset ($P<0.03$), and after adjusting for age, sex, and other disease characteristics, IgG index was also positively associated with serum 25(OH)D levels ($\beta=9.2$, $SE=4.0$, $P=0.03$; **Table 3**).

Discussion

Our findings show no association between serum 25(OH)D levels and age at MS onset, consistent with previous studies [3,11]. CSF IgG index was associated with age at onset, but this may be due to an association with age, as samples were taken near onset. IgG index have previously been shown to be negatively correlated with age among healthy individuals [12]. However, correlation with age was mainly attributed to a drop in IgG index above 45 years of age, and therefore unlikely to explain the association to age at onset as most patients in this cohort were below 45 years old. Our findings are also supported by an international multi-cohort study observing a

similar negative correlation between IgG index and age at onset [13]. However, this association will require further validation in consideration of both age and disease duration.

Relapsing disease and sex were partly dependent on sampling time in this cohort resulting in a bias affecting the previously reported associations with serum vitamin-D levels [10]. Although this could be a random occurrence, annual fluctuations in vitamin D and sun exposure have been associated with relapse rate [14], emphasizing the importance of correcting vitamin D measures for the time of sampling in future studies, particularly with a small sample size. It also showcases the effect of bias that occurs from non-randomized sampling where exploratory variables are confounded by variability in sampling protocol, in this case, resulting in a significant association in the opposite direction.

Although patients were sampled near the first symptom onset, measures may not represent actual disease onset due to a likely period of sub-clinical disease activity. However, a study looking at predicted lifelong residential UVB exposure observed no association to age at MS onset [15]. Genetic association studies and the recent popularity of genetic instruments may provide a reasonable proxy of vitamin D levels prior to onset. Still, a recent Danish study showed no association between age at onset and genetic susceptibilities to vitamin D deficiency, further refuting the role of vitamin D with age at MS onset [8].

In conclusion, these findings indicate serum vitamin D levels were not associated with age at onset, and that it is crucial to correct for seasonal variation of vitamin D to prevent misrepresented conclusions resulting from potential sampling bias.

Disclosure

PS, K, and JH reports no conflicts of interest.

Acknowledgments

We would like to thank Soilu-Hanninen and colleagues for the data used in this study [10]. PS was supported by a grant from Magreta af Ugglas foundation, IK and JH were supported by a Horizon 2020 EU grant (MultipleMS project number 733161). JH was partly supported by an endMS Doctoral Studentship (EGID:3045) from the Multiple Sclerosis Society of Canada.

References

1. Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: more than just the effects of vitamin D. *Nat Rev Immunol.* 2011;11(9):584-96.
2. Bäärnhielm M, Hedström AK, Kockum I, et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. *Eur J Neurol.* 2012;19(7):955-62.
3. van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. *BMJ.* 2003;327(7410):316.
4. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. *Ann Neurol.* 2007;61(6):504-13.
5. Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. *J Neurol Neurosurg Psychiatry.* 2011;82(10):1132-41.
6. Islam T, Gauderman WJ, Cozen W, Hamilton AS, Burnett ME, Mack TM. Differential twin concordance for multiple sclerosis by latitude of birthplace. *Ann Neurol.* 2006;60(1):56-64.
7. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA.* 2006;296(23):2832-8.
8. Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB. Association between age at onset of multiple sclerosis and vitamin D level-related factors. *Neurology.* 2016;86(1):88-93.
9. Brenton JN, Koenig S, Goldman MD. Vitamin D status and age of onset of demyelinating disease. *Mult Scler Relat Disord.* 2014;3(6):684-8.

10. Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. *Mult Scler*. 2005;11(3):266-71.
11. Tao C, Simpson S, Taylor BV, et al. Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. *Front Neurol*. 2018;9:418.
12. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. *Eur Neurol*. 1993;33(2):129-33.
13. Goris A, Pauwels I, Gustavsen MW, et al. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. *Brain*. 2015;138(Pt 3):632-43.
14. Spelman T, Gray O, Trojano M, et al. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. *Ann Neurol*. 2014;76(6):880-90.
15. Amram O, Schuurman N, Randall E, et al. The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset. *Mult Scler Relat Disord*. 2018;21:30-4.

Table 1. Summary characteristics of MS patients.

Variable	Mean $\pm$ SD [range] / n (%)
N	40
+ Relapsing-remitting disease	38 (95%)
+ Primary progressive disease	2 (5%)
Female	32 (80%)
Age (years)	36.5 $\pm$ 9.0 [18-53]
Age at first symptom (years)	33.8 $\pm$ 9.2 [18-53]
Age at diagnosis (years)	36.7 $\pm$ 9.1 [18-53]
Disease duration (years)	2.6 $\pm$ 3.5 [0-13]
Disease duration, $\leq$ 1 year	24 (60%)
EDSS $\geq$ 2	14 (35%)
OCB presence	32 (82.1%)
CSF IgG Index	1.15 $\pm$ 0.76 [0.40-4.82]
Serum 25(OH)D level (nmol/L)	49.6 $\pm$ 19.4 [17.0-95.0]
Serum 25(OH)D level (adj)* (nmol/L)	47.8 $\pm$ 17.7 [4.4-77.6]

* adj. serum 25(OH)D levels adjusted for seasonal variation.

Figure 1. Seasonal variation of serum 25(OH)D levels and its effect on the sampling of relapse/remission patients.

The scatter-plot illustrates the seasonal variation in serum 25(OH)D levels among all MS patients, along with the proportion sampled during relapse and of male sex (red) for each month below. A smoothed fitted line (dotted, loess method) with 95% confidence interval (grey interval) are plotted along with fitted periodic regression model of $\sin(2\pi x/12) + \cos(2\pi x/12)$ (solid). Reported significance are of the difference between relapse and remission MS patients determined by a Student t-test for either unadjusted or seasonal variation adjusted serum 25(OH)D levels.

Table 2. Multivariable linear regression of age at MS symptom onset on serum 25(OH)D levels adjusted for season of sampling and disease characteristics.

Variables	Univariable			Multivariable*		
	β	SE	P	β	SE	P
Age	0.95	0.06	8.4E-18	-	-	-
Sex, female	3.67	3.65	0.32	6.39	4.23	0.14
Serum 25(OH)D - Unadj.	0.05	0.08	0.52	-	-	-
Serum 25(OH)D - Adj	0.01	0.08	0.91	0.06	0.10	0.56
Relapsing activity	0.88	3.05	0.77	-0.77	3.41	0.82
OCB (+)	-4.19	3.85	0.28	1.02	4.32	0.81
CSF IgG index	-4.79	1.80	0.011	-5.35	2.31	0.028
EDSS ≥ 2	-0.13	3.10	0.96	0.72	3.32	0.83

Associations reaching statistical significance (P<0.05) are highlighted in bold.

* All the variables listed were included in the final model.

Table 3. Multivariable linear regression of serum 25(OH)D levels.

Variable	Unadjusted						Season adjusted					
	Univariable			Multivariable*			Univariable			Multivariable*		
	β	SE	P	β	SE	P	β	SE	P	β	SE	P
Age	0.25	0.35	0.47	0.11	0.36	0.75	0.046	0.32	0.89	0.196	0.321	0.55
Sex, female	19.28	7.12	0.010	14.41	8.64	0.11	-13.00	6.78	0.063	-6.36	7.75	0.42
Relapsing activity	-13.90	5.98	0.026	-11.50	6.14	0.071	12.04	5.29	0.029	12.89	5.51	0.026
OCB (+)	-1.73	7.75	0.82	8.00	8.29	0.34	2.06	7.20	0.78	-7.87	7.44	0.30
CSF IgG index	-1.66	4.11	0.69	-6.07	4.45	0.18	3.46	3.72	0.36	9.24	3.99	0.028
EDSS ≥ 2	-3.15	6.50	0.63	5.37	6.39	0.41	4.09	5.92	0.49	-6.01	5.74	0.30

Associations reaching statistical significance ($P < 0.05$) are highlighted in bold. Adjusted serum 25(OH)D levels were adjusted for seasonal variability using a periodic regression model of $\sin(2\pi x/12) + \cos(2\pi x/12)$, with “x” defined by the month of sampling.

* All the variables listed were included in the final model.